Kelly C. Hewitt
Rating: 4.9 of 5
( out of 46 reviews )

Kelly C. Hewitt, MD, FACS

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital North

2K, Breast Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
801-587-4241
Get Directions

  • Kelly Hewitt, MD, FACS, is a breast surgical oncologist at University of Utah Health and Huntsman Cancer Institute specializing in the surgical care of malignant and benign breast disease and management and surgical care of ductal carcinoma in situ (DCIS).

    Dr. Hewitt received her undergraduate degree from Johns Hopkins University and went to Georgetown University for her medical degree. She then completed her surgical residency at the University of Utah and received fellowship training in breast surgical oncology at the University of California, San Francisco.

    Dr. Hewitt’s research interests include minimizing overdiagnosis and overtreatment of DCIS and investigating ways to understand which patients require surgery and who may be managed with active surveillance. She is also involved in clinical trials for early-stage breast cancer and improving access to care throughout the Mountain West. She is a national co-principal investigator for the DCIS:RECAST clinical trial.

    Dr. Hewitt strives to provide personalized surgical care by working closely with her patients. She helps them understand their condition and treatment options, collaborating to create a surgical plan that aligns with their personal goals while ensuring optimal care for their disease.

    In her free time, Dr. Hewitt enjoys trail running, mountain biking, snowboarding, curling up on the couch with a good book, and attending her kids’ activities.

    Specialties

    Board Certification

    American Board of Surgery

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 46 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    SOUTH JORDAN HEALTH CENTER
    Rating: 5 out of 5

    Dr. Hewitt was very kind, professional and clear in communicating the best treatment in my case. It was so helpful to better understand my situation and have all questions answered in way that provided confidence. I would highly recommend her to anyone needing treatment.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Hewitt was very kind and open for any questions.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Hewitt took her time to explain everything and made me very comfortable

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    She was so understanding and very thorough in her answers and explanations. My family and I like very much.

    SOUTH JORDAN HEALTH CENTER
    Rating: 5 out of 5

    Dr. Hewitt is amazing and really cares about her patients.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Great review of what was happening and possible ways of treatment

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very very good at what she does.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    I would recommend her to anyone needing her services. Very respectful and professional in explaining procedures that will benefit the patient in the process.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    She was very informative. Helped in making my plan for treatment. Personable. Easy to trust her judgment. She showed empathy.

  • Kelly Hewitt, MD, FACS, is a breast surgical oncologist at University of Utah Health and Huntsman Cancer Institute specializing in the surgical care of malignant and benign breast disease and management and surgical care of ductal carcinoma in situ (DCIS).

    Dr. Hewitt received her undergraduate degree from Johns Hopkins University and went to Georgetown University for her medical degree. She then completed her surgical residency at the University of Utah and received fellowship training in breast surgical oncology at the University of California, San Francisco.

    Dr. Hewitt’s research interests include minimizing overdiagnosis and overtreatment of DCIS and investigating ways to understand which patients require surgery and who may be managed with active surveillance. She is also involved in clinical trials for early-stage breast cancer and improving access to care throughout the Mountain West. She is a national co-principal investigator for the DCIS:RECAST clinical trial.

    Dr. Hewitt strives to provide personalized surgical care by working closely with her patients. She helps them understand their condition and treatment options, collaborating to create a surgical plan that aligns with their personal goals while ensuring optimal care for their disease.

    In her free time, Dr. Hewitt enjoys trail running, mountain biking, snowboarding, curling up on the couch with a good book, and attending her kids’ activities.

    Board Certification and Academic Information

    Academic Departments Surgery -Associate Professor (Clinical)
    Academic Divisions Surgical Oncology
    Board Certification
    American Board of Surgery

    Education history

    Undergraduate Biology - Johns Hopkins University B.A.
    Professional Medical Medicine - Georgetown University School of Medicine M.D.
    Residency General Surgery - University of Utah School of Medicine Resident
    Fellowship Breast Surgical Oncology - University of California, San Francisco School of Medicine Fellow

    Selected Publications

    Journal Article

    1. Hewitt K, Lin H, Faraklas I, Morris S, Cochran A, Saffle (2014). Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections. Journal of burn care & research, 35(2), e106-11. (Read full publication)
    2. Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill S (2014). Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure. HPB, 16(1), 62-9. (Read full publication)
    3. Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar R (2021). Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience. Annals of surgical oncology, 28(5), 2555-2560. (Read full publication)
    4. Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar R (2022). Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies. American journal of surgery, 223(4), 699-704. (Read full publication)
    5. Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar R (2023). Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial. Annals of surgical oncology, 30(11), 6401-6410. (Read full publication)
    6. Addae JK, Sweeting RS, Meszoely IM, McCaffrey RL, Kauffmann RM, Kelley MC, Grau AM, Hewitt (2024). Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience. Breast cancer research and treatment, 204(1), 117-121. (Read full publication)
    7. Hewitt K, Son J, Glencer A, Borowsky AD, Cooperberg MR, Esserman L (2020). The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. Cancer epidemiology, biomarkers & prevention, 29(12), 2463-2474. (Read full publication)
    8. Solís O, Addae J, Sweeting R, Meszoely I, Grau A, Kauffmann R, Kelley M, McCaffrey R, Hewitt (2024). Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ. Breast cancer research and treatment, (Read full publication)
    9. Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Grou (2024). Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Annals of surgical oncology, (Read full publication)
    10. Kuo MC, Sims J, Solis OK, Meszoely IM, Sweeting RS, Grau AM, Hewitt KC, Kauffmann RM, Kelley MC, McCaffrey R (2024). Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ. Breast cancer research and treatment, (Read full publication)

    Letter

    1. Scaife CL, Hewitt K, Sheng X, Russell KW, Mone M (2015). Should we operate for an intra-abdominal emergency in the setting of disseminated cancer?. Surgery, 158(3), 636-45. (Read full publication)
    2. Scaife CL, Hewitt K, Sheng X, Russell KW, Mone M (2016). Reply: Should we operate for an intraabdominal emergency in the setting of disseminated cancer?. Surgery, 159(3), 981-3. (Read full publication)

    Abstract

    1. Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, ISPY2 Locoregional Working Group, Boughey J (2024). ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy-Results from the I-SPY2 Clinical Trial. Annals of surgical oncology, (Read full publication)